XML 44 R38.htm IDEA: XBRL DOCUMENT v3.24.3
Collaboration Agreements, License Agreement and Revenues - Product Revenue, Net - Additional Information 1 (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue $ 46,333 $ 40,134 $ 152,877 $ 120,614  
Contract with Customer, Liability [Abstract]          
Deferred revenue, net of current 126,219   126,219   $ 157,555
Net unbilled milestone and co-development revenue 25,804   25,804   0
Constrained for Future Recognition [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue 12,500 2,300 33,100 1,100  
Product Revenue, Net [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue 46,210 $ 29,390 126,391 $ 77,439  
China [Member] | Product Revenue, Net [Member]          
Contract with Customer, Liability [Abstract]          
Contract with customer liability increase decrease in revenue due to changes to estimated variable consideration 4,500        
AstraZeneca Agreements [Member]          
Contract with Customer, Liability [Abstract]          
Deferred Revenue 146,967   146,967   179,851
Deferred revenue, net of current 147,000   147,000    
Net unbilled milestone and co-development revenue 1,000   1,000   22,500
AstraZeneca Agreements [Member] | China [Member]          
Contract with Customer, Liability [Abstract]          
Deferred Revenue $ 22,100   $ 22,100    
Beijing Falikang Pharmaceutical Co Ltd | Product Revenue, Net [Member]          
Contract with Customer, Liability [Abstract]          
Reductions to gross accounts receivable         $ 3,000